On September 19, 2022 Targovax and our sector reported that we invite you to an Investor Event Tuesday 27 September 2022 (Press release, Targovax, SEP 19, 2022, View Source [SID1234619634]). DNB will provide an analyst’s view of the biotech industry followed by presentations from Targovax with a focus on circRNA. We will finish the event with an opportunity for you to speak with members of our management team in an informal setting with food and refreshments.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Targovax’s management team will present in Norwegian and are available for questions during the social event.
Date: Tuesday 27 September
Time: 17.00-19.00
Location: Sentralen, Øvre Slottsgate 3, Oslo
An analyst’s view of the biotech market
Dr. Geir Hiller Holom, Senior Equity Analyst at DNB Markets
Targovax Business Overview
Dr. Erik Digman Wiklund, CEO of Targovax
Circular RNA (circRNA) – the new frontier in RNA therapeutics discovered in Scandinavia
Dr. Thomas Hansen, VP Research at Targovax
There will be an informal Q&A and serving of food from 17:45.
Lubor Gaal, CFO og Andreas Storsve, VP Business Development, will also be present.